Naobios and Sumagen Canada Inc., a subsidiary of CreoSG Co., Ltd, have achieved a critical milestone in the development of Sumagen’s HIV-1 vaccine candidate, SAV001. This genetically modified, whole-killed HIV vaccine has shown both tolerance and safety in phase I trials, marking a significant step forward in what could potentially be a groundbreaking development in HIV treatment. Despite encountering initial delays due to the Covid-19 pandemic, the teams at Naobios and Sumagen remarkably managed to stay on schedule. This success has allowed Naobios to plan for cGMP production, with subsequent phase I/II clinical trials targeted for completion by the end of 2025.
Collaborative Efforts Driving Success
Naobios and Sumagen Canada Inc., a branch of CreoSG Co., Ltd, have reached a pivotal milestone in developing Sumagen’s HIV-1 vaccine candidate, SAV001. This vaccine, a genetically altered, whole-killed HIV formulation, demonstrated both tolerance and safety in its phase I trials. This achievement signifies a major leap forward and holds promise for groundbreaking advancements in HIV treatment. Although they faced delays because of the Covid-19 pandemic, the teams at Naobios and Sumagen impressively maintained their timeline. This accomplishment has allowed Naobios to plan for cGMP (current Good Manufacturing Practice) production, with the next phase of clinical trials—phase I/II—expected to conclude by the end of 2025. This journey reflects the dedication and resilience of both companies as they strive for medical innovations that could significantly impact HIV treatment. As the research progresses, it brings hope to those affected by HIV, signaling a potential turning point in the fight against the virus.
